Experiment 954945

Details

PropertyValue
Pharmacology
Administration routeIV INFUSION
OrganismEmpty organism
CitationSTEWART,JA: LOW,JB: ROBERTS,JD: BLOW,A:. (1991). A PHASE I CLINICAL TRIAL OF DIDEMNIN B.. 68(12)
Amount utilized
Compound isolated
Disease35 PATIENTS WITH ADVANCED CANCER WERE USED IN THIS PHASE I STUDY. THE DAILY DOSE LEVELS RANGED FROM 0.03 TO 2.00 MG/M2. DOSE LIMITING TOXICITIES WERE NAUSEA AND VOMITING. OTHER TOXICITIES INCLUDED ELEVATED HEPATIC ENZYME LEVELS, LEUKOPENIA, DIARRHEA, THROMBOCYTOPENIA, ANAPHYLACTIC SYMPTOMS AND INCREASED CLOTTING TIME.
Dose amountVAR
Number1
Qualitative result.
AnimalHUMAN ADULT
Dose expressionDOSE